CLINICAL THERAPIES

Five investigational immunotherapies targeting a range of types of cancers.

Axalimogene Filolisbac
ADXS-DUAL

Advaxis’ lead Lm Technology™ immunotherapies axalimogene filolisbac and ADXS-DUAL target HPV-associated cancers and are in clinical trials for four potential indications.

LEARN MORE

ADXS-PSA

ADXS-PSA is under investigation for targeting the prostate-specific antigen (PSA) associated with prostate cancer and is in clinical development both as a monotherapy and in combination with immune checkpoint inhibitors for the treatments of metastatic castration-resistant prostate cancer (mCRPC).

LEARN MORE

ADXS-HER2

Advaxis is developing ADXS-HER2 to target human epidermal growth factor receptor 2 (HER2)-expressing cancers. HER2 is expressed in certain solid-tumor cancers, including some breast, gastric, and esophageal cancers and osteosarcoma.

LEARN MORE

SURVIVOR STORIES

Hear the personal stories of men and women who have fought cancer with axalimogene filolisbac in clinical trials.

LEARN MORE

Partnerships

Advaxis has embraced strategic collaborations with other major biopharmaceutical companies for the development and commercialization of some of its proprietary cancer immunotherapies. In addition, Advaxis is developing numerous distinct proprietary immunotherapies directly or in partnership with recognized cancer centers of excellence and with support from advocacy foundations.

NEOANTIGENS

Taking advantage of recent advances in genome sequencing with the capacity to target all of a patient’s immunogenic cancer neoepitopes, Advaxis’ has two candidates utilizing neoepitopes: 

ADXS-NEO (in partnership with Amgen)
ADXS-HOT

 

LEARN MORE

STAY TUNED

Mailing List

Sign up for email alerts for Press Releases and Advaxis breaking news.


SOCIAL

Follow Us

Stay up to date on the latest events, news, and happenings on Advaxis and Immunotherapy.